Highly efficient serum-free manipulation of miRNA in human NK cells without loss of viability or phenotypic alterations is accomplished with TransIT-TKO

Breanna K. V. Hargreaves¹, Sarah E. Roberts², Beata Derfalvi¹,²*, Jeanette E. Boudreau¹,³*

¹ Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada, ² Department of Pediatrics, Dalhousie University, Halifax, Canada, ³ Department of Pathology, Dalhousie University, Halifax, Canada

* These authors contributed equally to this work.

Abstract

Natural killer (NK) cells are innate lymphocytes with functions that include target cell killing, inflammation and regulation. NK cells integrate incoming activating and inhibitory signals through an array of germline-encoded receptors to gauge the health of neighbouring cells. The reactive potential of NK cells is influenced by microRNA (miRNA), small non-coding sequences that interfere with mRNA expression. miRNAs are highly conserved between species, and a single miRNA can have hundreds to thousands of targets and influence entire cellular programs. Two miRNA species, miR-155-5p and miR-146a-5p are known to be important in controlling NK cell function, but research to best understand the impacts of miRNA species within NK cells has been bottlenecked by a lack of techniques for altering miRNA concentrations efficiently and without off-target effects. Here, we describe a non-viral and straightforward approach for increasing or decreasing expression of miRNA in primary human NK cells. We achieve >90% transfection efficiency without off-target impacts on NK cell viability, education, phenotype or function. This opens the opportunity to study and manipulate NK cell miRNA profiles and their impacts on NK cellular programs which may influence outcomes of cancer, inflammation and autoimmunity.

Introduction

Natural killer (NK) cells are potent effectors for maintenance of immune homeostasis, with influences in successful pregnancy, control of autoimmunity, and protection against cancer and viral infections. NK cell functions range from regulation to inflammation, and include cytokine production and cytotoxicity through direct binding and degranulation, promotion of apoptosis and antibody-dependent cellular cytotoxicity (ADCC) [1, 2].
The outcome of an NK-target interaction is determined by the NK cells’ integration of simultaneous signaling through germline-encoded activating and inhibitory receptors. Receptor expression is not universal across all of the NK cells in an individual’s repertoire: up to 30,000 phenotypically-distinct NK cell subsets have been defined in a single donor [3]. The functional potential of individual NK cells is calibrated by their capacity for inhibition by “self” human leukocyte antigens (HLA) in a process called “education” or “tuning” [1, 4, 5]. This creates a repertoire of NK cells in each individual comprised of NK cells differently equipped to respond to immunologic challenges [1, 6, 7]. In response to certain viruses and haptens, NK cells can form memory-like or “adaptive” populations that are long-lived and exhibit enhanced responsiveness upon rechallenge [8–10]. NK cells are highly plastic, and have clear potential for the immunotherapy of cancer, infectious disease and autoimmune disorders, but further study is needed to understand how to best and broadly control NK cell responsiveness.

At rest, and especially in response to cytokine pre-priming, NK cells encode an array of pre-formed mRNA for effector molecules including cytokines, granzymes and signaling receptors. MicroRNAs (miRNAs) can bind to and suppress mRNA translation; this enables post-transcriptional control for dynamic modulation of NK cell function [11]. MiRNAs are found throughout body fluids and cells, evolutionarily conserved and highly stable [12]. A single miRNA can have hundreds of targets, so miRNA enable modulation of cellular processes by impacting an array of mRNA species [13]. As a result, miRNAs have multifactorial impacts on human health and, when dysregulated, can underlie autoimmune diseases, antiviral immunity and cancer [14, 15].

The broad regulation of cellular processes by miRNA make them intriguing as agents to modulate NK cells for immunotherapy and to monitor ongoing processes. Already, miRNA species have been implicated as biomarkers for identifying and characterizing diseases or monitoring treatment efficacy [16–18]. Noteworthy, one miRNA-based treatment, miravirsen, is being tested against hepatitis C (clinicaltrials.gov # NCT02508090). Miravirsen is an antisense oligonucleotide that interferes with miR-122, a miRNA that otherwise facilitates persistence of viral RNA [19]. This trial proves the principle that it is feasible to deliver, manipulate and measure miRNA species, for clinical applications. As central mediators of inflammation and regulation and with functions controlled by miRNA, NK cells are an ideal target population for miRNA-based therapies, but further studies are required to understand how miRNA impact NK cell function.

Approaches are established for expansion, engineering and delivery of NK cells [20–22], but strategies to efficiently target miRNA in particular are lacking. Tailoring of the miRNA environment in NK cells may allow control in complex cellular processes to polarize NK cells for inflammation or regulation. As with many cell subtypes, transfection and engineering of primary NK cells has been challenging, and can induce alterations in NK cell biology and function as the NK cell responds to the transfection process or reagents [23]. These off-target impacts may alter NK cell function, with consequences on the efficacy of the desired intervention or interpretation of experiments. Few studies have altered miRNA in primary human NK cells, possibly owing to a lack of efficient methods for this purpose. Non-viral methods include lipid-based (lipofectamine, HiPerfect) [24–26] or mechanical (i.e. electroporation, nucleofection) [27]. A limited array of miRNA have been assessed using these methods, and the highest reported transfection efficiencies are 35% [26]. Noteworthy, among all published studies, cells were maintained in serum-enriched media. For investigations of miRNA in particular, it is important to avoid introduction of highly-conserved exogenous miRNA from serum [28], necessitating that all miRNA manipulations must be conducted in serum-free media. Approaches that enable manipulation of miRNA without substantially altering NK cell
Aiming to develop a technique to efficiently engineer NK cells through manipulation of miRNA, we tested four approaches. We modified expression of two miRNA species with known links to both human health and NK cell function: miR-155-5p and miR-146a-5p and tested their ability to change the miRNA landscape without altering population variation, NK cell education and hallmarks of NK cell adaptation. We found that the TransIT-TKO transfection reagent—a tool originally designed to deliver siRNA into cells—far outperformed other transfection approaches. Using fluorescein (FAM)-labeled miRNA, we demonstrate that >90% of unmanipulated, primary human NK cells can be transfected in this way, with maintenance of >80% viability. NK cell phenotype, repertoire diversity and education remained intact following transfection, confirming that this approach is highly-effective for engineering of NK cells without off-target impacts. To our knowledge, this represents the highest efficiency transfection of primary NK cells. We expect that this simple approach will accelerate miRNA engineering in NK cells for their use in immunotherapy and discovery research.

**Methods**

**Ethics**

Peripheral blood was collected from healthy donors locally and in collaboration with Canadian Blood Services’ Blood4Research program. Fibroblast-like synoviocytes (FLS) were collected from juvenile idiopathic arthritis (JIA) patients. The study was approved by the research ethics boards of the Dalhousie University, IWK Health Center and Canadian Blood Services and all participants or their guardians signed informed consent.

**Cell isolation, cell lines and culture**

PBMCs were isolated by density gradient centrifugation and NK cells were isolated from fresh heparinized blood sample using the RosetteSep Human NK Cell Enrichment Cocktail (Stemcell Technologies), according to the manufacturer’s instructions. We compared ATCC recommended media (containing 25% bovine and horse serum) and RPMI media (containing 10% FBS) to serum-free X-VIVO 10 media (Lonza) to define conditions for cell cultures without serum. Unless otherwise indicated, primary PBMCs and NK cells were maintained in X-VIVO 10 Serum-free Hematopoietic Media containing L-glutamine (3mM, Gibco), L-serine (1.8mM, Alfa Aesar), L-asparagine (0.6mM, Multicell), and 100 IU/mL IL-2 (Peprotech) at 1-2x10^6 cells/mL at 37˚C and 5% CO₂. Previously frozen PBMCs were rested overnight and NK cells rested for a minimum of 2 hours prior to experimental manipulation(s).

FLS were isolated from whole synovial fluid collected from patients with polyarticular or oligoarticular JIA using established protocols developed with modifications [29]. Briefly, cells were pelleted from whole synovial fluids (1000xg, 15 min) and mononuclear cells were isolated by density gradient centrifugation. Synovial Fluid MNCs were plated for 24 hours and non-adherent cells were removed. Adherent cells were maintained in alpha-MEM containing 20% HI FBS, NEAA, 1 μM sodium pyruvate, penicillin/streptomycin, and 2 μM L-glutamine (all from Gibco). Once confluent, we confirmed that FLS cell lines were homogeneous by flow cytometry phenotyping: CD14-negative, CD90 positive, Cadherin 11 positive. Thereafter, cells were used for experimentation at passage four and transferred to serum-free media, (X-Vivo 10) 24 hours prior to transfection.

The NK cell line, NK-92 (ATCC), was maintained in ATCC recommended media and cultured in X-VIVO 10 for experiments. The K562 target cell line was obtained from the National Cancer Institute and maintained in RPMI with 10% FBS.
Transfection

To identify the ideal procedure for manipulating miRNA in human NK cells, we tested several approaches, including the Amaxa Human NK Cell Nucleofector Kit (Lonza), Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher Scientific), TransIT-SiQuest Transfection Reagent (Mirus), and TransIT-TKO Transfection Reagent (Mirus), all following the manufacturer’s recommended protocols. All optimization transfections for miRNAs were completed with 25 nM of FAM-labeled Negative Control miRCURY LNA miRNA Mimic (Qiagen) in X-VIVO media compared to reagent only and no transfection controls. For all transfections, viability was assessed by trypan blue exclusion and flow cytometry, and efficiency was determined by flow cytometry. Based on these results, TransIT-TKO was optimized for primary human NK cell transfection with sense and anti-sense miRNAs.

Briefly, 1x10⁶ NK cells were resuspended in 510 μL X-VIVO media containing 100 IU/mL IL-2. In a separate sterile, RNase free, microfuge tube, 50 μL Opti-MEM Reduced serum media (ThermoFisher Scientific) was combined with 1 μL TKO reagent and 25 nM FAM-labelled negative control, mimic (sense) or antisense miRNA (Qiagen) and incubated in the dark for 20 minutes. The Opti-MEM-TKO-miRNA solution was added dropwise to the cells and the plate was rocked gently. Transfected NK cells were incubated for a minimum of 18 hours and maximum of 4 days at 37˚C under 5% CO₂ conditions.

Molecular biology

Mimic (sense) and antisense (inhibitors) for miRNA or a negative control mimic were obtained from Qiagen (miRCURY LNA miRNA Mimics/Inhibitors with FAM label, S1 Table). To confirm and quantify sense and antisense miRNA delivery post NK cell transfection, miRNA expression was assessed by real time quantitative PCR (RTqPCR). Total RNA, including miRNA, was isolated using the miRNeasy Mini Kit including an on-column DNase digestion (Qiagen) as described by the manufacturer. RNA was tested for quantity and quality using a NanoDrop spectrophotometer prior to cDNA synthesis. To create cDNA, a miScript II RT kit (Qiagen) was used according to manufacturer’s instructions. The final cDNA template was diluted 1/10 and stored at -20˚C. To confirm that there was no DNA contamination, all cDNA reactions included at least one reaction that omitted the reverse-transcriptase, (no RT control), and this cDNA was run for all miRNA targets and reference genes to confirm that no PCR product was made. RTqPCR reaction mixtures contained molecular grade sterile water, 1x SsoAdvanced Universal SYBR Green Supermix, 0.25 mM forward and universal reverse primers, and 5 μL of the appropriate cDNA template. Reference genes, miR-103a-3p and miR-191-5p, were selected by GeNorm algorithm [30, 31], RTqPCR cycles (S2 Table) were completed with CFX Connect real-time PCR detection system (BioRad) and analyzed with CFX Maestro software. All primer sequences and annealing temperatures can be found in S3 and S4 Tables.

Flow cytometry

To assess possible phenotypic and functional changes to the cells, NK cells transfected with the negative control miRNA mimic were stained and assessed by flow cytometry. Antibodies, clones and concentrations used are shown in S4 Table. Non-specific binding was prevented by incubation with 1.3 mg/mL Fc Block containing a mixture, (1:1) of human IgG and heat aggregated IgG, (CSL Behring) at 4˚C. After 15 minutes, surface stains, prepared in brilliant stain buffer (BD Bioscience), were added directly to the cells, and the cells were incubated in the dark for a further 20 minutes. The cells were washed with 1x PBS and stained with eBioscience fixable viability dye (ThermoFisher) for 30 minutes at 4˚C then washed in staining buffer (5
min, 700 x g). In some experiments, the cells were stained intracellularly using the Fixation/Permeabilization Solution kit (BD Bioscience) according to the manufacturer’s instructions. Following staining, cells were resuspended in 1% paraformaldehyde for fixation. Flow cytometers in the Dalhousie University’s CORE facilities (BD FACS Canto II or BD Fortessa with BD FACSDIVA software), were used for all flow cytometry data collection and data were analyzed using FlowJo 10.5 software.

Degranulation and cytotoxicity assays

To assess possible changes in NK cell function after TransIT-TKO transfection, we performed cytotoxicity assays using K562 to measure direct killing [32], and Rituximab (RTX)-coated autologous B cells to measure ADCC [33]. Prior to each assay, target cells (K562 or RTX-coated B cells) were stained with cell trace violet (CTV) (Thermofisher). Negative control mimic transfected and non-transfected NK cells were co-cultured with CTV-stained target cells such that the NK to target cell ratio was 1:1, and centrifuged at 200 x g for 3 minutes to promote cell-cell contact. K562 co-cultures were incubated for 5 hours and autologous PBMC co-cultures were incubated for 2 hours with or without 5 μg/mL RTX. Both co-cultures were maintained in X-VIVO 10 media with anti-LAMP1 (CD107a) antibody. To assess functional results (cytotoxicity and degranulation) co-cultures were stained for flow cytometry analysis.

Statistical analysis

All statistical analyses were conducted on either normalized RTqPCR relative gene expression or flow cytometry geometric means as appropriate. Samples were tested for normality with the Shapiro-Wilk normality test, and passed normality if $\alpha = 0.05$. If the data passed normality, analysis of variance (ANOVA) and parametric matched ratio paired $t$ tests were completed. If the data did not pass normality, paired non-parametric Wilcoxon tests were performed. Data for all statistical tests was deemed significant if $p < 0.05$.

Results

Establishment of serum-free growth conditions for primary human NK cells

MiRNAs are extremely conserved, often having exact or highly homologous sequences across mammalian species. We compared the sequences for miR-155-5p and miR-146a-5p between humans, cows, horses and mice: species whose serum is most often used in the culture of human NK cells. As expected, there is extensive inter-species conservation for these miRNA (S5 Table). To avoid introduction of extraneous miRNAs through culture and/or transfection, we developed serum-free culture conditions for primary human NK cells.

NK-92 and primary human NK cells were cultured for up to four days, and cellular viability was assessed by trypan blue exclusion and flow cytometry (S1 Fig). NK-92 cells grown in X-VIVO and RPMI maintained a viability of 95% but cells grown in ATCC recommended media exhibited a decreased viability of 85% after four days. Surprisingly, primary NK cells grown in X-VIVO media maintained a higher viability (92±2%) than those cultured in ATCC media (87±7%) after four days of culture. Cellular viabilities did not significantly differ between the ATCC recommended media for the NK-92 cell line or primary human NK cells and all subsequent experimentation was therefore conducted using serum free X-VIVO 10 media.
TransIT-TKO outcompetes other transfection techniques for delivering sense and antisense miRNAs to primary human NK cells

To determine the best technique for primary NK cell transfections, we compared the efficiency and viability of multiple transfection techniques, including lipofectamine, nucleofection, TransIT-SiQuest, and TransIT-TKO, a reagent created for delivery of siRNA (Fig 1). We used a fluorescein (FAM)-labeled control miRNA which encodes only a “scramble” sequence (i.e. no specific miRNA) to compare transfection approaches. The FAM label was included in this and all transfections (control, mimic and antisense). FAM allowed us to track transfection efficiency as the proportion of FAM+ among viable NK cells after transfection, and persistence of labeled oligonucleotides. Among the transfection methods tested, only TransIT-TKO could introduce miRNA efficiently (93.4±2.9% transfected), and without substantial mortality among recipient cells (93±2.8% viable at 2.5 days post-transfection). Similar transfection efficiencies were obtained for scramble oligonucleotide controls and all miRNA mimics and inhibitors used in subsequent experiments. To our knowledge, this is the most efficient transfection of NK cells reported.

We were surprised by the high and consistent miRNA NK cell transfection efficiencies without compromise to cellular viabilities achieved by TransIT-TKO. To determine whether this reagent was universally effective for delivery of miRNA, we tested its utility for transfecting FLS and primary PBMCs (S2 Fig). Between all three cell types we achieved an average viability of 94.2±5% and efficiency of 98.4±0.3%. TransIT-TKO successfully transfected both hematopoietic and non-hematopoietic cells, indicating its universal utility for delivery of mimic or antisense miRNA species.

miRNA-155-5p and miRNA-146a-5p expression can be controlled by transfection with TransIT-TKO

We next sought to alter the miRNA microenvironment in NK cells by introducing mimic miRNA or antisense miRNA to increase or silence expression of specific miRNA species, respectively. For this experiment, we elected to alter expression of miRNA-155-5p or miR-146a-5p, two miRNA species known to impact NK cell function [11, 34]. Following transfection with sense miRNA-155-5p or miR-146a-5p, we observed ~1000-fold and sustained increases in expression of these miRNA species in primary human NK cells (Fig 2A and 2B). Persistent expression of the transfectant-encoded FAM protein was observed in over 90% of cells by flow cytometry and similar between cells transfected with scramble or miRNA-modifying oligonucleotides. Furthermore, RT-qPCR revealed quantitative changes in the expression of intracellular miRNAs: delivery of the antisense miRNAs led to a significant decrease in the quantity of miRNA-146a-5p transcripts (0.3±0.08, p = 0.0288) and a trend toward decreased miRNA-155-5p (0.23±0.28) in transfected cells.

To determine whether these changes could impact miRNA targets, we measured STAT-1 and IRAK-1 mRNA expression in cells after transfection with miRNA-146-5p mimic or scrambled control oligonucleotide. As predicted, both STAT-1 and IRAK-1, direct targets of miRNA-146-5p [35, 36], were diminished 18h after transfection (Fig 2C). Taken together, these results reveal that miRNA species can be quickly manipulated in primary human NK cells.

The distribution of NK cell subsets is not altered by miRNA transfection

To study the impacts of miRNA on NK cell function, a technique that can alter miRNA while preserving normal NK cell function and phenotype is needed. We compared NK cells
Fig 1. TransIT-TKO outcompetes other transfection techniques. RosetteSep isolated primary human NK cells were transfected with 25 nM FAM-labeled negative control (scramble oligonucleotide) for 24 hours using nucleofection (red circle), lipofectamine (blue square), TransIT-SiQuest (black diamonds), or TransIT-TKO (green triangles). A-B) Cellular purity, viability, and transfection efficiency was assessed by flow cytometry. C-E) Comparison of transfection efficiencies and viabilities between transfection techniques. Plots represent individual transfection attempts, bars represent mean ± standard deviation. Data was assessed by one-way ANOVA (C) and unpaired t tests (D-E).

https://doi.org/10.1371/journal.pone.0231664.g001
transfected with a non-specific negative control mimic to non-transfected cells to determine whether TransIT-TKO or the introduction of exogenous miRNA nonspecifically influences the phenotype of NK cells. After 2.5 days, we measured and compared the phenotype of NK cells from the same donor after each treatment (Fig 3). Recognizing the extensive donor to donor variation that occurs, we compared the distribution of NK cell subsets before and after transfection with matching based on donor. Our first flow cytometry panel tested the distribution of the inhibitory KIR and NKG2A receptors, which are known to be important for NK cell education (Fig 3A). In our second panel, we queried markers of adaptive/memory NK cell populations (Fig 3B). Neither phenotypic analysis exhibited substantial changes in response to transfection, indicating that this highly-efficient technique for miRNA manipulation does not skew NK cell population frequencies.

**NK cell cytotoxic function by missing self-responsiveness and ADCC are not impacted by miRNA transfection**

To ascertain whether transfection changed the reactive function of NK cells, we tested whether missing self-responsiveness was altered by transfection. We tested populations from the same donor with and without stimulation using the HLA-negative NK cell target K562 (Fig 4). As expected, NK cells responded to the “missing ligand” target, K562 with increased IFN-γ production and degranulation (CD107a externalization) compared to unstimulated cells. Consistent with previous observations [37], granzyme B was depleted after degranulation of NK cells. Importantly, the introduction of negative control miRNA mimics did not alter the magnitude of this missing self-reactivity among NK cells. Hence, TransIT-TKO transfection can be used to alter the miRNA landscape without non-specifically impacting the fundamental physiology of NK cells.

A major feature of NK cells is their ability to mediate antibody-dependent cellular cytotoxicity (ADCC). We tested NK cell-mediated ADCC by incubating NK cells with and without transfection of negative control miRNA mimics with autologous B cells in the presence of anti-CD20 (Rituximab, RTX). Similar to missing self-responsiveness, NK-mediated ADCC
Fig 3. TransIT-TKO transfection with negative control mimic does not impact NK cell phenotypes and distribution. RosetteSep isolated human NK cells were transfected with Negative Control Mimic for 2.5 days with TransIT-TKO. NK cell phenotypic markers were assessed by flow cytometry and donors were genotyped for HLA.

https://doi.org/10.1371/journal.pone.0231664.g003
was not altered by TransIT-TKO transfection or the introduction of non-targeting miRNA mimics (Fig 5). Taken together, these functional studies confirm that the impacts of miRNA sense or antisense strands to NK cells is highly effective and does not lead to off-target impacts on NK cells. Therefore, this approach to alter the NK miRNA microenvironment will be useful in determining the specific impacts of miRNA species on NK cell function.

Fig 4. Missing self reactivity is not impacted by miRNA transfection. NK cells were isolated form healthy human donors and transfected for 2.5 days using a negative control miRNA mimic, or mock transfected. Thereafter, NK cells were challenged with the HLA-negative target K562 and IFN-γ and degranulation were measured. NK cells predicted to be educated based on donor HLA are shown as hollow circles; NK cells predicted to be uneducated are shown as filled symbols. Each donor is represented by a unique color.

https://doi.org/10.1371/journal.pone.0231664.g004
**Fig 5. Scrambled oligonucleotide transfection has no effect on NK cell function.** RosetteSep isolated human NK cells were transfected with scrambled oligonucleotide using TransIT-TKO methodology and incubated for 2.5 days. Transfected and non-transfected NK cells were cultured alone, with K562 cells (1:1) or with autologous PBMCs such that the B cell to NK cell ratio was 1:1 with and without RTX (anti-CD20). A) Targeted cell death was assessed by flow cytometry. B) NK cells degranulation was assessed by surface expression of CD107a and was measured by flow cytometry. Dots represent individual healthy donors, bar graphs represent mean ± SD. Data was assessed by two way ratio paired t tests.

https://doi.org/10.1371/journal.pone.0231664.g005
Discussion

MicroRNA are presenting as important and complex controllers of immune function, particularly in NK cells. Studying miRNA is challenging because of their numerous and heterogeneous impacts, but understanding them may open the possibility of miRNA-based therapy or NK cell manipulation for control of cellular processes. Research on miRNA has been bottlenecked by a lack of ideal approaches to alter the miRNA landscape without off-target effects. We report that both primary NK cells and the NK-92 cell line can be efficiently transfected for alterations of miRNA in serum-free conditions. Cellular viability, phenotype and function are maintained for at least four days in cell culture, and NK cells exhibit increases or decreases in specific miRNA expression after introduction of sense or antisense miRNA, respectively.

Using a negative miRNA mimic control, we show that miRNA introduction and the use of TransIT-TKO alone do not alter NK cell function for missing-self reactivity or ADCC, or significantly impact the distribution of NK cell populations. Taken together, this work represents a novel and highly efficient technique for manipulating the miRNA environment in NK cells that will facilitate studies of miRNA impacts on NK cells.

In this study, we focused on two miRNA species with known impacts on NK cell function: miR-146a-5p and miR-155-5p. These species are generally associated with negative and positive feedback on NK cell activation, respectively. MiRNA-146a-5p is activated through NFκB and inhibits pro-inflammatory responses, including production of type I IFN, IL-1β and TNF, by regulating TRAF6 and STAT1; this in turn regulates NK cell function and maturation [38, 39]. In contrast, miR-155-5p is most commonly associated with pro-inflammatory features, including increasing production of IFN-γ and TNF production [40]. Here, we demonstrate that the expression of these miRNA species can be altered within 18h of transfection, with impacts on expression of mRNA for their target genes. Given the pleiotropic and dynamic nature of miRNA programs, altering them may provide broad changes in immunologic programs that would be beneficial in therapeutic applications or informative in disease processes.

Capable of immune polarization, target cell killing and self-tolerance, NK cells are attractive as tools for immunotherapy. NK cells do not require strict HLA matching, and have not been associated with substantial toxicity or off-target effects and may therefore be applicable as off-the-shelf adoptive cell therapies [22, 41, 42]. Increasingly, there is interest in engineering NK cells (i.e. chimeric antigen receptors or cytokines), for fit-for-purpose applications in immunotherapy [21]. Despite their advantages NK cell-based clinical trials have yielded heterogeneous results, likely reflecting further obstacles, such as immunosuppression in a tumor microenvironment, that hinder their reactivity [43, 44]. Analysis of miRNA transcriptomes from NK cells derived from peripheral blood, cord blood, and uterine decidua reveal significant differences in miRNA profiles, suggesting that miRNA may help to calibrate and tailor NK cell effector functions. Manipulation of miRNA profiles may complement ongoing engineering by allowing control of intracellular networks to buffer environmental signals and allow persistent NK cell migration, reactivity or regulation [18].

The high stability of miRNA, and that it is released and available in body fluids make it attractive candidates as biomarkers or for targeted therapies [16–18]. Although transfection techniques are numerous, efficient transfection of primary NK cells without introducing off-target effects or skewing the NK cell population remains challenging. In NK cells, transfection is associated with TLR activation, reduced NK cell function and apoptosis, as NK cell pattern recognition receptors respond to components of the delivery vector or the oligonucleotides themselves [23, 45]. Viral transfection can efficiently and permanently deliver a transgene of interest, but typically requires activation and/or proliferation of NK cells, and repeated infections and long culture times to be effective [23]. Noteworthy, lentiviral transduction requires...
ongoing cellular division [46], which is incompatible with understanding the impacts of miRNA on resting NK cells. These infections and long culture times can have unintended consequences, convey insertional mutagenesis or alter the distribution or function of NK cell subsets inadvertently, and require strict safety precautions [45, 47]. Hence, for short-term study or alteration of miRNA in primary NK cells, non-viral transfections are desirable.

In our hands, only TransIT-TKO could efficiently transfect primary NK cells with high efficiency without substantial loss of viability. To our knowledge, the introduction of miRNA to NK cells using the TransIT TKO system represents the most efficient transfection method for alteration of miRNA in primary NK cells, outcompeting other methods of oligonucleotide delivery, including non-viral transfection methods. In our analysis, we assessed markers both of NK cell education (i.e. KIRs, NKG2A, LIR-1) and adaptation/memory (i.e. NKG2C, CD57, CD2, PLZF) [8, 9], finding that none are substantially altered through transfection alone. This opens the possibility to study the role(s) of miRNA or clusters of miRNA in NK and other cell types without substantial alterations from their resting state.

The magnitude of targeted miRNA reduction with use of miRNA inhibitors was less than that of the increase prompted by transfection of sense miRNA. This could reflect that these anti-sense miRNAs may bind to and inhibit miRNA translational repression of mRNA without initiating the miRNA degradation. Due to limitations in the viability and persistence of NK cells in vitro, we were unable to measure the impacts or persistence of transfected miRNA mimics or inhibitors beyond 2.5 days in these experiments. However, as miRNA are thought to act relatively quickly to repress mRNA in cells (i.e. 12-24h) [48], a 2.5-day window may nonetheless be sufficient to study the impact of miRNA on NK cell function.

NK cells are potent immune effectors already known to be important for controlling the outcomes of pregnancy, infection and cancer. Distinct NK cell subsets drive inflammation or impact immunoregulatory functions, and restrict adaptive immune responses that may otherwise lead to autoimmunity [49–51]. Variation in NK cell function within and between individuals is known to correspond with diversity in health outcomes, making this population highly interesting for study and precise immunotherapy. Our approach for genetic manipulation of primary human NK cells that introduces minimal changes in NK cell function, phenotype or viability, and can be completely conducted using serum-free media, presenting the possibility of manipulating NK miRNA to understand its roles, and to tailor NK cell function.

Supporting information
S1 Fig. X-VIVO serum free media best supports NK cell growth for cellular transfections. NK-92 cells (Top) and RosetteSep isolated primary human NK cells (Bottom) were grown in ATCC recommended media (containing 25% serum) and serum free X-VIVO media for up to 4 days. A/C) Images represent magnification with 20x objective lens. C/D) Cellular viability were assessed by trypan blue exclusion. Data represents individual (B) or mean (D) values ± standard deviation, n = 1–3. Data was assessed by t test, ns indicates no significance. (DOCX)

S2 Fig. TransIT-TKO is effective for transfection of lymphocytes and fibroblasts. Rosette-Sep isolated primary human NK cells (A) primary human PBMCs (B) and primary JIA FLS (C) were transfected with miR-146a-5p sense or antisense miRNA compared to non-transfected control cells. A-C) Cellular viability, purity, and efficiency were determined by flow cytometry. D) MiRNA delivery was assessed by RTqPCR. Baseline reflects expression level of mi-146a-5p in cells transfected with negative control miRNA. Fold changes compared to negative were calculated using two reference miRNAs and the Pfaff Method. Data represents individual measurements and bars represent mean ± standard deviation, n = 1–3. RTqPCR results

PLOS ONE | https://doi.org/10.1371/journal.pone.0231664 April 17, 2020 13/17
were assessed by one-way ratio paired t tests.

S1 Table. Qiagen miRCURY LNA sense and antisense miRNA sequences.

S2 Table. Primer sequences, efficiencies, and annealing temperatures for miRNA.

S3 Table. Primer sequences, efficiencies, and annealing temperatures for mRNA.

S4 Table. Flow cytometry antibodies, dyes and labels.

S5 Table. Non-exhaustive MiRBase sequence blast.

Acknowledgments

We sincerely thank the healthy blood donors for their contribution to this project and gratefully acknowledge the Dalhousie University Faculty of Medicine Flow Cytometry CORE facility, Derek Rowter, Renee Raudonis and Fang Liu for technical assistance with this project.

Author Contributions

Conceptualization: Breanna K. V. Hargreaves, Beata Derfalvi, Jeanette E. Boudreau.

Data curation: Breanna K. V. Hargreaves, Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Formal analysis: Breanna K. V. Hargreaves, Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Funding acquisition: Beata Derfalvi, Jeanette E. Boudreau.

Investigation: Breanna K. V. Hargreaves, Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Methodology: Breanna K. V. Hargreaves, Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Project administration: Beata Derfalvi, Jeanette E. Boudreau.

Resources: Beata Derfalvi, Jeanette E. Boudreau.

Supervision: Beata Derfalvi, Jeanette E. Boudreau.

Validation: Breanna K. V. Hargreaves, Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Visualization: Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

Writing – original draft: Breanna K. V. Hargreaves, Beata Derfalvi, Jeanette E. Boudreau.

Writing – review & editing: Sarah E. Roberts, Beata Derfalvi, Jeanette E. Boudreau.

References

1. Boudreau JE, Hsu KC. Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol. 2018; 39(3):222–39. https://doi.org/10.1016/j.it.2017.12.001 PMID: 29397297
2. Morandi F, Horenstein AL, Chillemi A, Quaroni A, Chiesa S, Imperatori A, et al. CD56brightCD16− NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. J Immunol. 2015; 195(3):965–72. https://doi.org/10.4049/jimmunol.1500591 PMID: 26091716

3. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemati-Gorgani N, Dogan OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013; 5(208):208ra145. https://doi.org/10.1126/scitranslmed.3006702 PMID: 24154599

4. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005; 436(7051):709–13. https://doi.org/10.1038/nature03847 PMID: 16079848

5. Boudreau JE, Mulrooney TJ, Le Luduec JB, Barker E, Hsu KC. KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV. J Immunol. 2016; 196(8):3398–410. https://doi.org/10.4049/jimmunol.1502469 PMID: 26962229

6. Boudreau JE, Hsu KC. Natural killer cell education in human health and disease. Curr Opin Immunol. 2018; 50:102–11. https://doi.org/10.1016/j.coi.2017.11.003 PMID: 29413815

7. Savoy SKA, Boudreau JE. The Evolutionary Arms Race between Virus and NK Cells: Diversity Enables Population-Level Virus Control. Viruses. 2019; 5(12):777. https://doi.org/10.3390/v110201303 PubMed Id: 30831403

8. Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity. 2015; 42(3):431–42. https://doi.org/10.1016/j.immuni.2015.02.013 PMID: 25786175

9. Schlums H, Cichocki F, Tesi B, Theorell J, Beziaut V, Holmes TD, et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity. 2015; 42(3):443–56. https://doi.org/10.1016/j.immuni.2015.02.008 PMID: 25786176

10. Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, Senman B, et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of hapten and viruses. Nat Immunol. 2010; 11(12):1127–35. https://doi.org/10.1038/ni.1953 PMID: 20972432

11. Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lander LL. MicroRNA function in NK-cell biology. Immunol Rev. 2013; 253(1):40–52. https://doi.org/10.1111/imr.12045 PMID: 23550637

12. Klinge C, Clauss S, Boddmann K, Jabbari R, Jabbari J, Riesgaard B, et al. Stability of Circulating Blood-Borne Micro-RNAs—Pre-Analytic Methodological Considerations. PLoS One. 2017; 12(2):e0167969. https://doi.org/10.1371/journal.pone.0167969 PMID: 28151938

13. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012; 149(3):515–24. https://doi.org/10.1016/j.cell.2012.04.005 PMID: 22541426

14. Long H, Wang X, Chen Y, Wang L, Zhao M, Lu Q. Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett. 2018; 428:90–103. https://doi.org/10.1016/j.canlet.2018.04.016 PMID: 29680223

15. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1:15004. https://doi.org/10.1038/sigtrans.2015.4 PMID: 29263891

16. Omar HA, El-Serafi AT, Hersi F, Arafa EA, Zaheer DM, Madkour M, et al. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. FEBS J. 2019.

17. Singh A, Patro PS, Aggarwal A. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis. Clin Rheumatol. 2019; 38(3):877–84. https://doi.org/10.1007/s10067-018-4380-z PMID: 30511295

18. Chen EB, Zhou ZJ, Xiao K, Zhu GQ, Yang Y, Wang B, et al. The miR-561-5p/CX3CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX3CR1(+) Natural Killer Cells Infiltration. Theranostics. 2019; 9(16):4779–94. https://doi.org/10.7150/thno.32543 PMID: 31367257

19. Janssens HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368(18):1685–94. https://doi.org/10.1056/NEJMoa1209026 PMID: 23534542

20. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekov PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012; 7(1):e30264. https://doi.org/10.1371/journal.pone.0030264 PMID: 22279576

21. Sieglar EL, Zhu Y, Wang P, Yang L. Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy. Cell Stem Cell. 2018; 23(2):160–1. https://doi.org/10.1016/j.stem.2018.07.007 PMID: 30075127

22. Lee DA. Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019; 290(1):85–99. https://doi.org/10.1111/imr.12793 PMID: 31355489

23. Carlsten M, Childs RW. Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Front Immunol. 2015; 6:266. https://doi.org/10.3389/fimmu.2015.00266 PMID: 26113846
24. Sourour SK, Aboelenein HR, Elemam NM, Abdelhamid AK, Salah S, Abdelaziz AI. Unraveling the expression of microRNA-27a* & NKG2D in peripheral blood mononuclear cells and natural killer cells of pediatric systemic lupus erythematosus patients. Int J Rheum Dis. 2017; 20(9):1237–46. https://doi.org/10.1111/1756-185X.13099 PMID: 28523761

25. Huang Q, Ding J, Gong M, Wei M, Zhao Q, Yang J. Effect of miR-30e regulating NK cell activities on immune tolerance of maternal-fetal interface by targeting PRF1. Biomed Pharmacother. 2019; 109:1478–87. https://doi.org/10.1016/j.biopha.2018.09.172 PMID: 30551399

26. Ma Y, Gong J, Liu Y, Guo W, Jin B, Wang X, et al. MicroRNA-30c promotes natural killer cell cytotoxicity via up-regulating the expression level of NKG2D. Life Sci. 2016; 151:174–81. https://doi.org/10.1016/j.lfs.2016.03.012 PMID: 26968781

27. Huang Y, Lei Y, Zhang H, Hou L, Zhang M, Dayton AI. MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood. 2011; 118(26):6793–802. https://doi.org/10.1182/blood-2011-05-356162 PMID: 22077060

28. Stenfeldt C, Arzt J, Smoliga G, LaRocca M, Gultoska J, Lawrence P. Proof-of-concept study: profiling of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection. Virol J. 2017; 14(1):71. https://doi.org/10.1186/s12985-017-0743-3 PMID: 28388926

29. Stebulis JA, Rossetti GG, Atez FJ, Zunier RB. Fibroblast-like synovial cells derived from synovial fluid. J Rheumatol. 2005; 32(2):301–6. PMID: 15693092

30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034.

31. De Spiegelaere W, Dern-Wieloch J, Weigel R, Schumacher V, Schorle H, Nettersheim D, et al. Reference gene validation for RT-qPCR, a note on different available software packages. PLoS One. 2015; 10(3):e0122515. https://doi.org/10.1371/journal.pone.0122515 PMID: 25825906

32. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods. 2007; 325(1–2):51–66. https://doi.org/10.1016/j.jim.2007.05.013 PMID: 17617419

33. Merkt W, Lorenz HM, Watzl C. Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting. Arthritis Res Ther. 2016; 18(1):206. https://doi.org/10.1186/s13075-016-1101-3 PMID: 27629249

34. Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013; 12(12):1160–5. https://doi.org/10.1016/j.autrev.2013.07.003 PMID: 23860189

35. Xu D, Han Q, Hou Z, Zhang C, Zhang J. miR-146a negatively regulates NK cell functions via STAT1 signaling. Cell Mol Immunol. 2017; 14(8):712–20. https://doi.org/10.1038/cmi.2017.113 PMID: 26996068

36. Chatzikyr iakidou A, Voulgari PV, Georgiou I, Drosos AA. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010; 71(5):382–5. https://doi.org/10.1111/j.1365-3083.2010.02381.x PMID: 20500689

37. Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, et al. Remodeling of secretory lysosomes during education tunes functional potential in NK cells. Nat Commun. 2019; 10(1):514. https://doi.org/10.1038/s41467-019-08384-x PMID: 30705279

38. Saba R, Sorensen DL, Booth SA. MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response. Front Immunol. 2014; 5:578. https://doi.org/10.3389/fimmu.2014.00578 PMID: 25484882

39. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016; 16(5):279–94. https://doi.org/10.1038/nri.2016.40 PMID: 27121651

40. Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol. 2013; 191(12):5904–13. https://doi.org/10.4049/jimmunol.1301950 PMID: 24227772

41. Fehninger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtisinger J, et al. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018; 24(8):1581–9. https://doi.org/10.1016/j.bbmt.2018.03.019 PMID: 29597002

42. Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 2019; 41(1):59–68. https://doi.org/10.1007/s00281-018-0721-x PMID: 30361801

43. Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Frontiers in Immunology. 2019; 10.
44. Ni F, Guo C, Sun R, Fu B, Yang Y, Wu L, et al. MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential regulator of NK cell function. Sci Rep. 2015; 5:9993. https://doi.org/10.1038/srep09993 PMID: 25909817

45. Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Front Immunol. 2019; 10:1205. https://doi.org/10.3389/fimmu.2019.01205 PMID: 31214177

46. Guven H, Konstantinidis KV, Alici E, Aints A, Abedi-Va lugerdi M, Christensson B, et al. Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol. 2005; 33(11):1320–8. https://doi.org/10.1016/j.exphem.2005.07.006 PMID: 16263416

47. Schlimgen R, Howard J, Wooley D, Thompson M, Baden LR, Yang OO, et al. Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. J Occup Environ Med. 2016; 58(12):1159–66. https://doi.org/10.1097/JOM.0000000000000879 PMID: 27930472

48. Hausser J, Syed AP, Selevsek N, van Nimwegen E, Jaskiewicz L, Aebersold R, et al. Timescales and bottlenecks in miRNA-dependent gene regulation. Mol Syst Biol. 2013; 9:711. https://doi.org/10.1038/msb.2013.68 PMID: 24301800

49. Zitti B, Bryceson YT. Natural killer cells in inflammation and autoimmunity. Cytokine Growth Factor Rev. 2018; 42:37–46. https://doi.org/10.1016/j.cyto.2018.08.001 PMID: 30122459

50. Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019; 18(3):306–11. https://doi.org/10.1016/j.autrev.2018.10.005 PMID: 30639645

51. Shahrabi S, Zayeri ZD, Ansari N, Hadad EH, Rajaei E. Flip-flops of natural killer cells in autoimmune diseases versus cancers: Immunologic axis. J Cell Physiol. 2019.